Weave Bio, a San Francisco, CA–based AI-native regulatory automation management solutions company, has secured $20 million in Series A funding.
Investors
The round was led by USVP, with participation from Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital.
USVP is a Silicon Valley venture capital firm founded in 1981 and headquartered in Menlo Park, California. The firm specializes in early-stage Series A and B investments across the technology and healthcare sectors. USVP’s core investment domains include cybersecurity, enterprise/cloud software (SaaS), consumer internet and e-commerce, and healthcare.
Weave Bio Use of Funds
The company will use the funding to enhance its AI-driven platform, expand into global regulatory markets, achieve full coverage of the therapeutic lifecycle, and grow its commercial team.
About Weave Bio
Led by CEO Brandon Rice, Weave Bio is an AI-native, cloud-based software company that provides an AI-native solution built to support regulatory workflows across the entire therapeutic lifecycle from IND preparation through market applications and post-market updates. Designed for pharmaceutical companies, biotech firms, CROs, and regulatory consultants, Weave infuses AI into every step from data extraction to dossier submission to deliver compliant, submission-ready documents with unprecedented speed. Founded in 2022, Weave Bio is headquartered in San Francisco, California.
Funding Details
Company: Weave Bio
Raised: $20.0M
Round: Series A
Funding Date: October 2025
Lead Investor: USVP
Additional Investors: Innovation Endeavors, Magnetic Ventures, Character, TMV, Serrado Capital
Company Website: https://www.weave.bio/
Software Category: Healthtech / Regulatory Automation
Source: https://www.businesswire.com/news/home/20251016053611/en/